HFpEF Definition
Heart failure with preserved ejection fraction (HFpEF) is defined as a clinical syndrome requiring: 1) symptoms and/or signs of heart failure, 2) left ventricular ejection fraction ≥50%, 3) elevated natriuretic peptides (BNP >35 pg/mL or NT-proBNP >125 pg/mL in ambulatory settings), and 4) objective evidence of cardiac structural/functional abnormalities or elevated left ventricular filling pressures. 1, 2, 3
Core Diagnostic Criteria
The most recent 2023 ACC Expert Consensus and 2022 AHA/ACC/HFSA guidelines establish that HFpEF diagnosis requires all four components working together 1, 3:
1. Clinical Presentation
Look specifically for:
- Dyspnea (especially exertional)
- Orthopnea and paroxysmal nocturnal dyspnea
- Peripheral edema (bilateral ankle swelling)
- Jugular venous distension
- Pulmonary rales
- S3 gallop rhythm
- Exertional intolerance
2. Preserved Ejection Fraction
- LVEF ≥50% is the threshold 1, 2, 3
- The cutoff is admittedly arbitrary, but this represents the current consensus
- Patients with LVEF 41-49% fall into a "mildly reduced" category (HFmrEF), not HFpEF 2, 3
3. Elevated Natriuretic Peptides
Ambulatory/non-acute setting 1, 2:
- BNP >35 pg/mL
- NT-proBNP >125 pg/mL
Hospitalized/acute setting 1, 2:
- BNP >100 pg/mL
- NT-proBNP >300 pg/mL
Critical caveat: Natriuretic peptide levels in HFpEF are typically lower than in HFrEF for the same degree of left ventricular end-diastolic pressure elevation, particularly in patients with higher BMI (which is prevalent in HFpEF) 1. This means you cannot rule out HFpEF based solely on "normal-ish" natriuretic peptides if other criteria are met.
4. Objective Cardiac Abnormalities
You must document structural and/or functional cardiac abnormalities 2, 3:
Structural evidence:
- Left atrial enlargement (increased left atrial volume index)
- Increased LV mass (LV mass index)
- LV hypertrophy
Functional evidence:
- Diastolic dysfunction on echocardiography (E/e' ≥15 is particularly useful)
- E/A ratio abnormalities
- Elevated filling pressures on invasive hemodynamic testing
Diagnostic Algorithm
Step 1: Evaluate clinical history, symptoms, physical exam, and ECG 2
- If all normal, HF is highly unlikely—stop and consider other diagnoses
- If any abnormal, proceed to Step 2
Step 2: Measure natriuretic peptides 2
- If below thresholds (BNP <35 or NT-proBNP <125), HF is unlikely
- If elevated, proceed to Step 3
Step 3: Echocardiography to assess LVEF and cardiac structure/function 2
- Confirm LVEF ≥50%
- Document structural abnormalities (LA enlargement, LV hypertrophy)
- Assess diastolic function (E/e' ratio, mitral inflow patterns)
Step 4: If diagnosis remains uncertain after Steps 1-3, consider provocative testing 2, 3:
- Exercise stress echocardiography to unmask elevated filling pressures
- Invasive hemodynamic exercise testing (gold standard but rarely needed in routine practice)
Critical Pitfalls to Avoid
Don't diagnose HFpEF based on symptoms alone—you need objective cardiac evidence. Many conditions mimic HF symptoms (obesity, deconditioning, pulmonary disease, anemia) 2.
Don't be falsely reassured by "borderline" natriuretic peptides in obese patients—obesity suppresses natriuretic peptide levels, and HFpEF patients generally have lower levels than HFrEF patients 1.
Don't forget to exclude HFpEF mimics 1:
- Infiltrative cardiomyopathy (amyloidosis, sarcoidosis)
- Hypertrophic cardiomyopathy
- Significant valvular disease (especially aortic stenosis, mitral regurgitation)
- Pericardial disease (constrictive pericarditis)
- High-output heart failure
- Primary kidney or liver disease causing volume overload
Recognize that HFpEF diagnosis is particularly challenging in elderly patients with multiple comorbidities and no obvious congestion at rest 2. These patients often require exercise testing to demonstrate elevated filling pressures.
Evolution from Older Definitions
The 2008 ESC guidelines required only three components: symptoms/signs, LVEF >45-50%, and evidence of diastolic dysfunction 4. The newer definitions add the mandatory requirement for elevated natriuretic peptides to improve diagnostic specificity 2, 3. This reflects recognition that symptoms alone are too non-specific, and objective biomarker evidence strengthens the diagnosis.
The Universal Definition of Heart Failure, adopted by the 2023 ACC guidelines, emphasizes that HFpEF requires either elevated natriuretic peptides or objective evidence of cardiogenic congestion (pulmonary or systemic), plus structural/functional cardiac abnormalities 1. This framework helps distinguish true HFpEF from other causes of dyspnea and edema.